Allergen specific immunotherapy

PreclinicalBiologic

UUniversity of Zurich

Allergen specific immunotherapy is one of 22 biologic programs targeting Allergy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyActive, not recruiting

AllergyPreclinical

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Allergy

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

1 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

6 3

Claritin

PPerrigo Company

Approved

1 4

Flagyl

DDePuy Orthopaedics

Approved

1 5

Potassium Citrate

MMission Pharmacal

Approved

1 6

Levaquin

WWim Janssens

Approved

1 7

Achromycin V

WWyeth-Lederle Vaccines

Approved

1 8

Allegra

CChattem

Approved

1 9

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 10

Lastacaft

AbbVie

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Recruiting

Pollen Allergy

NCT06876506

Clinical

Trials by Indication[1]

Allergy1 trial

The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunotherapy

Unknown status·UUniversitas Airlangga·N/A·NCT05450289·40 enrolled

Immunotherapy1 trial

A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy

Completed·UUniversity of Zurich·Phase 2·NCT00470457·156 enrolled

Pollen Allergy1 trial

Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy

Recruiting·HHull University Teaching Hospitals NHS Trust··NCT06876506·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Allergen specific immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allergen specific immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allergen specific immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Zurich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Zurich

Allergen specific immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Allergy1 trial

Immunotherapy1 trial

Pollen Allergy1 trial

References

Drug Info

Quick Facts

Related News